financetom
Business
financetom
/
Business
/
Infibeam Avenues gets NCLT nod for demerger of SME E-commerce Services, marketplace biz
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Infibeam Avenues gets NCLT nod for demerger of SME E-commerce Services, marketplace biz
Nov 28, 2020 1:02 PM

Fintech firm Infibeam Avenues Ltd (IAL) on Saturday said it has received approval from the National Company Law Tribunal (NCLT), Ahmedabad, for demerger of its various entities, including SME e-commerce service and e-commerce business undertaking.

Under the 'Composite Scheme of Arrangement', IAL had sought to demerge its SME E-commerce as well as the E-commerce marketplace businesses to Suvidhaa, while theme park and event business will be demerged and vested to DRC Systems.

Under the scheme, all IAL shareholders (on the record date of December 11, 2020) will be allocated additional shares of Suvidhaa Infoserve Ltd and DRC Systems India Ltd without any additional cost, IAL said in a statement on Saturday.

Suvidhaa will issue 197 equity shares for every 1,500 equity shares to the shareholders of IAL, while DRC will issue 1 equity share for every 412 equity shares to IAL shareholders, it added.

The composite scheme of arrangement is effective from the appointed date i.e. April 1, 2020, and the record date has been set as December 11, 2020, the statement said.

"The Composite Scheme of Arrangement will assist Infibeam Avenues to unlock value for its shareholders. Subject to regulatory approvals, Suvidhaa and DRC will get listed on the stock exchanges ie BSE and NSE," it added.

IAL will continue to focus on the high growth, highly scalable and profitable fintech business of digital payments and enterprise software platforms, it said.

Last year, the Board - on the recommendation of the Audit Committee - had considered and approved the Composite Scheme of Arrangement and received observatory consent and approval from the stock exchange in July, 2020 for filing with the NCLT, the statement said.

Suvidhaa provides last mile financial services to more than 40 million customers through both offline and online delivery channels. It will leverage its existing offline capabilities to scale the product business of Infibeam Avenues and focus on niche product verticals with margins. Infibeam will leverage the physical retail location of Suvidhaa to offer last mile logistics across the country.

Shapoorji Pallonji Mistry is an angel investor and owns minority stake in Suvidhaa, as per the information in the statement.

DRC Systems offers cloud enterprise ERP solutions, customised software for e-commerce applications, web technology analysis, mobile technology analysis including testing in several programming languages, services across e-commerce, content management system, payment processing system and others.

The company is profitable and has operations in India, the US, Germany, the Netherlands and the Middle East region.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Marker Therapeutics Stock Drops After Report About Lymphoma Treatment
Marker Therapeutics Stock Drops After Report About Lymphoma Treatment
Aug 26, 2025
Marker Therapeutics, Inc. ( MRKR ) on Tuesday provided an update on the progress and clinical observations from the Phase 1 APOLLO study investigating MT-601, a Multi-Antigen Recognizing (MAR)-T cell product, in patients with lymphoma who have relapsed after anti-CD19 CAR-T cell therapy or for whom anti-CD19 CAR-T cell therapy is not an option. Last year, Marker Therapeutics ( MRKR...
Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data
Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data
Aug 26, 2025
Regeneron Pharmaceuticals, Inc. ( REGN ) on Tuesday shared data from the Phase 3 NIMBLE trial assessing investigational cemdisiran monotherapy in adults with generalized myasthenia gravis (gMG). gMG is a rare, chronic autoimmune disease that causes weakness in voluntary muscles, affecting the eyes, face, neck, arms, legs, and breathing. The trial met the primary and key secondary endpoints. Cemdisiran is...
What's Going On With ImmunityBio Shares Tuesday?
What's Going On With ImmunityBio Shares Tuesday?
Aug 26, 2025
ImmunityBio, Inc. ( IBRX ) shares are trading higher Tuesday after the company announced its chemotherapy-free combination showed 100% disease control results and is planning a Phase 2 trial. What To Know: ImmunityBio ( IBRX ) reported early findings from five patients with recurrent glioblastoma, a deadly form of brain cancer, who were treated with its immune-boosting regimen combining ANKTIVA,...
Citi Trends Lifts Outlook As CEO Highlights Robust Back-To-School Sales Momentum
Citi Trends Lifts Outlook As CEO Highlights Robust Back-To-School Sales Momentum
Aug 26, 2025
Citi Trends, Inc. ( CTRN ) reported second-quarter sales of $190.75 million (+8% year over year) on Tuesday, beating the analyst consensus estimate of $188.397 million. Comparable store sales in the quarter under review increased by 9.2% compared to the same quarter in the year-ago period, driven by traffic, basket, and conversion increases. “Our second quarter results underscore our recent success...
Copyright 2023-2026 - www.financetom.com All Rights Reserved